Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study

Haemophilia

Volumn 23, Issue 3, 2017, Pages 458-465

  Hillarp, A ^a   Bowyer, A ^b   Ezban, M ^c   Persson, P ^c   Kitchen, S ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c NOVO NORDISK A S   (Denmark)

Author keywords

chromogenic FVIII assay; N8 GP; one stage FVIII assay; polyethylene glycol; turoctocog alfa; turoctocog alfa pegol

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8; MACROGOL DERIVATIVE; RECOMBINANT FACTOR VIII N8;

ARTICLE; CHROMOGENIC FACTOR XIII ASSAY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG POTENCY; HEMATOLOGY TEST KIT; HEMOPHILIA A; HUMAN; LABORATORY; MEASUREMENT ACCURACY; ONE STAGE FACTOR XIII ASSAY; PRIORITY JOURNAL; BLOOD ANALYSIS; BLOOD CLOTTING; CHEMISTRY; DRUG EFFECTS; METABOLISM; PARTIAL THROMBOPLASTIN TIME; PROCEDURES;

BLOOD CHEMICAL ANALYSIS; BLOOD COAGULATION; FACTOR VIII; HUMANS; PARTIAL THROMBOPLASTIN TIME; POLYETHYLENE GLYCOLS;

EID: 85013149291     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.13168     Document Type: Article

References (22)

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1–47.
2. Tiede A. Half-life extended factor VIII for the treatment of hemophilia A. J Thromb Haemost 2015; 13(Suppl 1): S176–9.
3. MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). National Hemophilia Foundation MASAC Document #241 2016: https://www.hemophilia.org/sites/default/files/document/files/241Prophylaxis.pdf dated 27 Feb 2016; Accessed July 6, 2016.
4. Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood 2015; 125: 2038–44.
5. Oldenburg J, Albert T. Novel products for haemostasis - current status. Haemophilia 2014; 20(Suppl 4): 23–8.
6. Tiede A, Brand B, Fischer R et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013; 11: 670–8.
7. Stennicke HR, Kjalke M, Karpf DM et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood 2013; 121: 2108–16.
8. Kitchen S, Signer-Romero K, Key NS. Current laboratory practices in the diagnosis and management of haemophilia: a global assessment. Haemophilia 2015; 21: 550–7.
9. Gu JM, Ramsey P, Evans V et al. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A. Haemophilia 2014; 20: 593–600.
10. Oldenburg J, Pavlova A. Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype. Hamostaseologie 2010; 30: 207–11.
11. Lochu A, Romari N, Beltran J, Magdelaine A, Ezban M, Hermit MB. Influence of FIX and FVIII PEGYLATION on FIX and FVIII activity based on APTT assays. J Thromb Haemost 2014; 11: 970.
12. Kitchen S, Gray E, Mertens K. Monitoring of modified factor VIII and IX products. Haemophilia 2014; 20(Suppl 4): 36–42.
13. Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646–50.
14. Mikaelsson M, Oswaldsson U. Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products. Semin Thromb Hemost 2002; 28: 257–64.
15. Caron C, Dautzenberg MD, Delahousse B et al. A blinded in vitro study with Refacto mock plasma samples: similar FVIII results between the chromogenic assay and a one-stage assay when using a higher cephalin dilution. Haemophilia 2002; 8: 639–43.
16. Lusher JM, Hillman-Wiseman C, Hurst D. In vivo recovery with products of very high purity–assay discrepancies. Haemophilia 1998; 4: 641–5.
17. Dodt J, Hubbard AR, Wicks SJ et al. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators. Haemophilia 2015; 21: 543–9.
18. Bowyer AE, Hillarp A, Ezban M, Persson P, Kitchen S. Measuring factor IX activity of nonacog beta pegol with commercially-available one-stage clotting and chromogenic assay kits: a two-center study. J Thromb Haemost 2016; 14: 1428–35.
19. Sommer JM, Buyue Y, Bardan S et al. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity. Thromb Haemost 2014; 112: 932–40.
20. Sommer JM, Moore N, McGuffie-Valentine B et al. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia 2014; 20: 294–300.
21. Mackie I, Cooper P, Lawrie A et al. Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Int J Lab Hematol 2013; 35: 1–13.
22. Viuff D, Barrowcliffe T, Saugstrup T, Ezban M, Lillicrap D. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia 2011; 17: 695–702.